| Title: | Revisiting antiplatelet therapy in acute carotid tandem lesions |
|---|
| Authors: | ID Zupan, Matija (Author)
ID Straus, Lara (Author)
ID Kermer, Pawel (Author)
ID Papanagiotou, Panagiotis (Author)
ID Frol, Senta (Author) |
|---|
| Files: |  PDF - Presentation file, download (382,40 KB)
MD5: EA09833A004E2428B4C97B1AA9D709D4
 URL - Source URL, visit https://www.mdpi.com/2077-0383/15/9/3195
|
|---|
| Language: | English |
|---|
| Typology: | 1.02 - Review Article |
|---|
| Organization: |  UKC LJ - Ljubljana University Medical Centre
|
|---|
| Abstract: | Background/Objectives: Acute carotid tandem lesions (TLs), defined by concurrent cervical internal carotid artery (ICA) stenosis or occlusion and intracranial large vessel occlusion, occur in 10–20% of patients undergoing mechanical thrombectomy (MT) for acute ischemic stroke (AIS). Optimal periprocedural antiplatelet management during emergent carotid artery stenting (eCAS) remains uncertain, particularly regarding the balance between preventing stent thrombosis and avoiding hemorrhagic complications. Methods: A narrative review was conducted using PubMed and Scopus (until 6 March 2026) to identify English-language studies evaluating antiplatelet therapies during eCAS for TLs. We included seven real-world studies and registry analyses. Data on study design, patient characteristics, procedural strategies, angiographic results, functional outcomes, and safety metrics were extracted. Results: No randomized controlled trials (RCTs) were identified. The available evidence is derived exclusively from observational studies. Across these cohorts, glycoprotein IIb/IIIa inhibitors (GPIs), particularly tirofiban, were generally associated with lower rates of in-stent thrombosis and higher reperfusion success, with symptomatic intracranial hemorrhage (sICH) rates that appeared comparable to or lower than those reported with acetylsalicylic acid (ASA). Cangrelor, an intravenous (IV) P2Y12 inhibitor, was associated with improved stent patency and increased likelihood of complete reperfusion, although reported effects on clinical outcomes were inconsistent when compared with GPIs or ASA. Aside from abciximab, potent IV antiplatelet agents did not consistently show an increased sICH signal. Oral dual antiplatelet therapy was also associated with improved technical outcomes without a clear excess in bleeding complications. Conclusions: Current real-world observational data suggest that rapid-acting IV antiplatelet agents—particularly GPIs and, increasingly, cangrelor—may represent feasible periprocedural options during eCAS for TLs, with potential benefits for technical success and no consistent evidence of increased hemorrhagic risk. However, interpretation is limited by study heterogeneity and non-randomized designs. The absence of RCTs highlights the need for prospective comparative studies and standardized periprocedural antiplatelet protocols. |
|---|
| Keywords: | acute carotid tandem lesions, acute ischemic stroke, antiplatelet therapy, cangrelor, glycoprotein IIb/IIIa inhibitors |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Year of publishing: | 2026 |
|---|
| Number of pages: | str. 1-14 |
|---|
| Numbering: | Vol. 15, iss. 9, [article no.] 3195 |
|---|
| PID: | 20.500.12556/DiRROS-29175  |
|---|
| UDC: | 616.8 |
|---|
| ISSN on article: | 2077-0383 |
|---|
| DOI: | 10.3390/jcm15093195 |
|---|
| COBISS.SI-ID: | 276171779 |
|---|
| Note: | Nasl. z nasl. zaslona;
Opis vira z dne 23. 4. 2026;
|
|---|
| Publication date in DiRROS: | 23.04.2026 |
|---|
| Views: | 34 |
|---|
| Downloads: | 21 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
